CLIENT: Mitsubishi Pharma Europe
Medical & Pharmaceutical PR Project

divider
Mitsubishi Pharma Europe Case Study

PROJECT

Launch Mitsubishi Pharma Europe’s anticoagulant Exembol® (argatroban) after it received acceptance for use as a treatment for patients with heparin-induced thrombocytopenia type II (HIT).

Strategy

HIT (type II) is a rare condition with potentially life threatening outcomes for patients. ROAD launched a media campaign targeting haematology, phlebotomy, ICU and cardiovascular trade titles and journals, to raise awareness of Exembol® as a new drug for the treatment of HIT.

Making A Healthy Difference

Articles were secured in Journal of Anaesthesia and the Journal of Intensive Care, and coverage was secured in 30+ targeted medical and pharmaceutical titles, generating 2,089,147 opportunities to be seen.

Our Work

Corporate

Consumer Brands

Pharmaceutical PR

Aesthetics & Beauty

NHS & Healthcare Services

Medical Tech & Innovation

Nutrition

Medical Education

Let's Talk

icon-smart-phone.png#asset:1419

Contact Paul Jarman (Managing Director)

paul@roadcommunications.co.uk

+ 44 (0)208 995 5832

Sign up to our newsletter